FAQ
Questions teams ask first.
Factual answers about scope, confidentiality, and how this connects to Alenvo.
Regulatory risk, clinical and nonclinical evidence quality, CMC readiness, safety signals, approval pathway clarity, data confidence, and deal-readiness signals. Outputs are structured to support expert review and decision-making.
Before the term sheet
Understand the asset risk before you commit capital.
A short conversation is enough to scope a meaningful diligence review, tailored to your asset stage and decision window.
No confidential information required to start the conversation.